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Abstract
Background: The study design and protocol that underpin a randomised controlled trial (RCT) are critical for the
ultimate success of the trial. Although RCTs are considered the gold standard for research, there are multiple threats
to their validity such as participant recruitment and retention, identifying a meaningful change, and non-adherence
to the protocol. For clinical RCTs, involving patients and clinicians in protocol design provides the opportunity to
develop research protocols that are meaningful to their target audience and may help overcome some of the
inherent threats in conducting RCTs. However, the majority of protocols do not describe the methodology
underpinning their development, limiting the amount of learned experience shared between research groups.
Method: With the purpose of reporting a collaborative approach towards developing a protocol, we present the
findings from three sequential workshops that were conducted with the aim of developing a protocol to
investigate the feasibility of adding a computerised test of attention, impulsivity and activity (QbTest) to medication
management of children and young people with Attention deficit hyperactivity disorder (ADHD). Based on previous
qualitative interviews with clinicians and families, each workshop prioritised topics for focused discussion.
Information from the workshops was fed back to the participants for reflection in advance of the next workshop.
Results: The workshops involved 21 multi-disciplinary ADHD experts, including clinicians, patient and public
involvement (PPI) members, parents of young people with ADHD and researchers. The consensus workshops
addressed key research issues such as: the most relevant outcome measures/ resource drivers; methods and time
points for data collection; and the clinical protocol for utilising the QbTest, including when best to use this within
the medication management process. The resulting protocol details a feasibility RCT design describing these factors.
Conclusion: Protocols which are co-developed may help overcome some of the risks associated with RCT
completion (e.g. recruitment, retention, protocol adherence) and help prioritise outcomes of greater relevance to
the populations under study. The methodology has potential value for researchers and organisations developing
clinical guidelines, and offers insights into the valuable impact of PPI upon trial design.
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Background
Although every clinical trial should be underpinned by a
rigorously developed protocol [1] there is little published
evidence or guidance on the development of randomised
controlled trial (RCT) protocols. Tezlaff et al. [1] outline
the range of stakeholders for whom well-constructed
protocols are pivotal, which include: trial participants,
researchers, ethics committees, research funders and
systematic reviewers. With the exponential growth of
evidence-based medicine since the term was first coined
in the early 1990s [2], there has been increasing acknow-
ledgment and preference for RCTs [3], which are often
advocated as the ‘gold standard’ in research designs.
However, there are multiple, well-reported pitfalls in con-
ducting RCTs, including: low participant recruitment, dif-
ferential drop-out across study arms, participants not
wishing to be randomised, developing a suitable control
intervention, identifying a meaningful change (that is of
importance to individuals seeking treatment), and non-
adherence to the protocol [4, 5]. In light of this, there is
growing recognition of the need to involve patients and
clinicians to improve the feasibility and acceptability of
trial protocols, develop protocols which are meaningful to
their target audience, and reduce the risk of trial failure.
Indeed, the importance of patient and public involvement
(PPI) in the early stages of trial design is recognised by
major funding bodies across Europe and America, and is
highlighted in National Institute for Health and Care Ex-
cellence (NICE) [6] guidelines.
PPI is increasingly recognised as a crucial part of re-
search, and is now a condition of funding for most (if not
all) health research within the UK. Inclusion of PPI goes
beyond simply improving trial design and conduct
(although this is one of its benefits), rather it reflects the
rights of citizens to have a say in research that might affect
their lives [7]. When meaningful PPI is achieved, it can
have a positive impact on the design, conduct and success
of research (including RCTs) [8]. Inclusion of PPI in the
research process can be challenging for various reasons
including experience and training of researchers, differing
expectations (amongst researchers and PPI members)
about the processes underpinning PPI, and its scope and
purpose [9]. Methods of involvement (and its subsequent
impact) vary widely, and there is increasing emphasis
placed on the need to both adequately report PPI (with
new guidance emerging to do this) [10], and assess its im-
pact. Evidence is slowly building about its impact – both
positive and negative – on the research process, research
outcomes, and the experience of both researchers and PPI
members themselves (see PiiAF guidance [11]). In the
spirit of elucidating the impact of PPI as one of a range of
voices in the protocol design process, this paper describes
the development of a trial protocol with attention paid to
the needs, opinions and rationale of the different expert
groups that fed into it.
Over the past few years there has been an increased
recognition of the importance of standardised reporting
of clinical trial protocols. To this end, the SPIRIT
(Standard Protocol Items: Recommendations for Inter-
ventional Trials) guidelines [12] were developed through
a series of Delphi consensus surveys, consensus work-
shops and a systematic review of the literature. The pri-
mary aim of the SPIRIT checklist was to increase the
rigour of reporting of trial protocols, however, the ma-
jority of protocols do not describe their methodological
development [1]. Providing details of how the protocol
was shaped and developed facilitates the opportunity for
critical appraisal of the trial design and provides a plat-
form for the sharing of learned-experiences across re-
search groups. This is critical for the improvement of
trial designs. It also highlights the potential impact of
PPI on trial design, which is increasingly important to
demonstrate.
The aim of this paper is to report the methodological
development of the protocol for a feasibility study, the
‘QbTest Utility in Optimising Treatment for ADHD’
(QUOTA) study [13]. The study aims to develop a medi-
cation management for stimulant medication and re-
search protocol for evaluation of the QbTest (described
in more detail below), and investigate the feasibility and
acceptability of the protocol when delivered in routine
healthcare services for children with attention deficit
hyperactivity disorder (ADHD) in the UK. To improve
outcomes, NICE ADHD guidelines recommend regular
monitoring of symptoms when children commence
medication [14]. However, research suggests that moni-
toring can be difficult in routine practice [15] and clini-
cians often rely on subjective information such as
reports from parents and teachers to ascertain improve-
ment [16]. These sources can be unreliable and difficult
to obtain. The addition of an objective test of attention
and activity (QbTest) may improve the objectivity, reliabil-
ity and speed of clinical decision-making [17–21], and so
reduce the time to identify the optimal medication dose.
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The QbTest combines a computer test of attention and
impulsivity with a measure of activity in order to assess
the three core symptom domains of ADHD: attention, im-
pulsivity and activity. The QbTest takes approximately 20-
min to complete and provides an instant report which
graphically displays summary score relevant to each symp-
tom domain (inattention, hyperactivity, impulsivity) with
reference to a large age- and gender-stratified normative
database. This report is available to download from the
Qbtech server within minutes of completion of the test.
The clinician is then able to discuss the test report imme-
diately with the family, or book a separate appointment to
discuss the report alongside the results of other question-
naire measures. Further details on the QbTest can be
found elsewhere [20]. Although research has indicated the
utility of the test to aid assessment and management of
ADHD [17–19, 22–24], there is a need to develop a stan-
dardised protocol for its use in routine clinical settings, in
line with Medical Research Council (MRC) guidance [25],
as well as to evaluate the feasibility of the protocol before
proceeding to a fully-powered clinical trial. To enable this,
the protocol for QUOTA was developed through work-
shops comprised of stakeholders and experts in ADHD.
The aim of this paper is not to evaluate the protocol per
se, but to describe the approach to co-creating a research
protocol with multi-disciplinary members. By reporting
and reflecting upon the key stages involved in these work-
shops, the resulting decisions and the rationale under-
pinning them, and the perspectives that they reflect, this
paper aims to inform the development of future research
protocols for RCTs of clinical interventions.
Method
The study team initially considered seeking expert opin-
ion through a Delphi method. However, due to time and
budgetary constraints, a workshop approach with mul-
tiple expert stakeholders was considered the most suit-
able option. Additionally, the team felt a workshop
approach would allow greater interaction and discus-
sion/reflection between members.
Workshop members
Members of the research team, who were study co-
applicants (MG, CLH, NB) invited 21 experts to attend
three workshops. Members were selected to ensure rep-
resentation from key stakeholders. The experts included
four PPI members (parents of young people with ADHD
whose children had received medication; including PPI
co-applicant and co-author NB), one education expert
with experience of using QbTest in schools, two repre-
sentatives and clinical advisors from Qbtech (on hand to
answer technical questions only), one health economics
expert with prior experience of ADHD studies, nine
healthcare professionals from a range of backgrounds
(including five consultant child and adolescent psychia-
trists, three consultant paediatricians and one nurse spe-
cialist - including co-authors CH, KS, KSe, JC), three
academic team members (MG, CLH, MJ), and two rep-
resentatives from National Institute for Health Research
(NIHR) MindTech MedTech Co-operative (MindTech)
(JLM and SB), who acted as facilitators and note-takers
and also brought additional PPI expertise to the work-
shop design. Not all experts attended every workshop.
The experts were informed that the aim of the work-
shops was to develop a medication protocol around
QbTest, including selecting key outcomes and resource
drivers that affect the child and their family. The feasi-
bility of the protocol would then be evaluated in a feasi-
bility RCT design, with the comparator being
assessment-as-usual. The finalised protocol for the
QUOTA study received ethical approval from West of
Scotland Research Ethics Committee (REC) 1 REC refer-
ence 17/WS/0209.
Selection of initial topics for discussion
The topics discussed at the workshops were based on
thematic analysis of interview data collected from clini-
cians and parents who had previously taken part in an
RCT of QbTest (this method and findings have been re-
ported elsewhere [12]). These interviews revealed a clin-
ical need to develop a more standardised approach to
medication management using QbTest. In particular,
they highlighted areas of uncertainty around; a) how,
why and when QbTest should be used in medication
management, b) how the optimum dose should be de-
fined, and c) which outcomes are most meaningful to
clinicians and families. One workshop was therefore
dedicated to explore each of these topics resulting in a
total of three workshops. When designing the work-
shops, content and format was driven by researchers, in
collaboration with a PPI co-applicant (NB) who had pre-
vious experience of PPI in ADHD research studies.
At the time the workshops were designed, the applica-
tion had undergone approval by the funding body
(NIHR) to ensure it was of acceptable scientific rigour. It
should be noted that not all study parameters were open
for group discussion. For example, the choice of QbTest
was not open for discussion, although other similar tests
are available, for a review see Hall et al. [18]. The re-
searchers also ensured that the evolving design was of
sufficient quality and was within the boundaries of a
feasibility RCT. Furthermore, clinical decisions around
dose and titration must always sit within current best
practice (i.e. NICE [6] guidelines) and follow the speci-
fied dosing schedule recommended for the drug. With
this in mind, although the protocol was limited to stimu-
lant medication, the choice of stimulant and its dosing
schedule was left to clinicians. The focus was specifically
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on the use of QbTest in everyday practice, which may vary
from clinician-to-clinician. In sum, the workshops were
designed to address specific details of the protocol whilst
recognising that some elements of the research design and
some aspects of clinical practice, cannot be changed.
Format of workshops
All workshops were held at the Institute of Mental
Health at the University of Nottingham in England. The
workshops took place between April – June 2017, with
one workshop being held every month. Each workshop
was scheduled to last for two hours.
Workshops were chaired by the Chief Investigator
(MG) and facilitated by a researcher outside the study
team (JLM). The facilitator’s primary role was to ensure
the voices of each member were heard, paying particular
attention to the inclusion of PPI members. The discus-
sions of the meetings were noted by research team
members CLH and SB as well as by JLM. The notes
were collated and summarised by CLH and checked for
accuracy by SB before being fed back to the group by
email for consideration and reflection in advance of the
next workshop.
In the first two workshops, members were initially di-
vided into two groups to aid discussions and ensure each
member had the chance to express their opinion. The
groups were divided to ensure mixed composition of ex-
pertise. Both groups fed back their discussions to the en-
tire workshop after initial discussions were completed,
allowing for further discussion, particularly in relation to
any areas of disagreement or uncertainty. In the second
workshop, the choice was made to have the groups dis-
cuss different topics due to time constraints, as there
was a need to cover sufficient content within the two
hour workshop. In order to ensure wide input and ‘con-
sensus’, each group fed back their discussion to the other,
including describing the rationale behind decisions, and
this was followed by facilitated discussion to debate and
refine decision making.
In the third (and final) workshop, members remained
as one group due to the comparatively low attendance
rate and the need to reflect as a whole on the final
protocol. The research team collated decisions and main
discussion points after each workshop and fed this back
to all members (regardless of whether they attended) be-
tween workshops. The start of the next workshop began
with a reflection of the discussions from the previous
workshop and the opportunity for members to raise any
further discussion points.
Results
Attendance at each workshop varied from 13 to 17 mem-
bers (62–81-% of those invited), but always included at
least four PPI members, a clinician and representatives
from the research team and MindTech. Participants who
could not attend were updated on the group discussion
via telephone or email by the Trial Manager.
Workshop 1: introduction and defining the medication
protocol
The aim of the first workshop was to reach consensus
on the medication protocol and therefore how best to
use QbTest alongside current clinical practice to moni-
tor the effects of stimulant medication.
The expert group (n = 15) consisted of six clinical
members, four PPI members, two researchers, two
MindTech representatives (as facilitator and note-taker)
and one clinical advisor from Qbtech. The group was di-
vided into two small groups consisting of seven mem-
bers per group, which included at least one
representative from each role (e.g. PPI, clinician, re-
searcher). The additional member was the clinical ad-
visor to Qbtech, who did not participate in group
decision-making (to avoid conflicts of interest), and was
present to provide expert advice on the use of the
QbTest if required. The groups were informed of the
aim of the workshop and given two points of guidance
in developing the protocol: 1) the medication protocol
must include a baseline assessment of symptoms prior
to medication initiation; 2) follow-up assessments should
be within 12-weeks from baseline (due to restrictions im-
posed by funding limitations). No other guidance was given.
The group were encouraged to develop a feasible and ac-
ceptable protocol based on their expertise in ADHD. In
order to provide some anchor points for discussion, the
groups were set three main questions to answer.
Q1: When should the first follow-up QbTest (on medi-
cation) take place?
The groups discussed when the first (baseline) QbTest
should be conducted. One clinician noted there is no
‘gold standard’ in assessing ADHD, and as such there
would likely be variation in clinical practice, with some
children already receiving a QbTest as part of their diag-
nostic assessment. Both clinicians and PPI members
raised concerns that if the child had already received a
QbTest during their initial diagnostic assessment it
would not be appropriate to attend an additional con-
sultation to repeat the test purely for the purpose of a
baseline assessment before starting medication. Con-
versely, clinicians also raised concerns that if the diag-
nostic assessment had taken place several weeks or
months previously, the QbTest may be ‘out of date’ and
not reflect current symptomatology. The Qbtech clinical
advisor was brought into the group to provide advice on
the reliability of QbTest results over repeated testing. It
was also noted by PPI members that there should, where
possible, be no delay in medication initiation as a result
of participating in a trial, and minimisation of additional
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appointments due to difficulties gaining permission for
time away from school. Thus, any clinic baseline meas-
ure (and consent) should be collected at the point the
family consent to take part in the study.
With regard to when the first follow-up QbTest should
be conducted, group one considered that 1–2 weeks after
medication initiation was ideal. In this group, the clinical
experts noted the importance of identifying early non- re-
sponders or partial responders to medication in order to
switch medications or increase dosages to facilitate early
optimal responding. This was supported by PPI members
who noted that they had often experienced a substantial
delay in receiving the ADHD diagnosis and were keen to
receive the most appropriate medication as soon as pos-
sible. In contrast, the second group had selected a longer
first follow-up of 6–8 weeks after medication initiation.
Although this group noted the importance of a telephone
review two weeks after starting medication, the clinicians
in this group raised concerns with the feasibility for clinics
of conducting a face-to-face follow-up assessment after
two weeks. PPI members in this group echoed the senti-
ments of those in group one, but they also noted that they
felt their child may be reluctant to sit two QbTests in
quick succession.
When the two groups presented their discussions back
to the whole workshop there were a range of critical fac-
tors discussed, including the need to monitor side-
effects quickly (an issue raised by both PPI members
and clinicians), to be able to adjust dose or switch to an
alternative medication as soon as possible if there was a
sub-optimal response (important to both PPI and clini-
cians), and the issue of limited clinic appointments avail-
able and/or families being unwilling to attend clinic too
frequently. All members were in unanimous agreement
that there would need to be some early checking of ad-
verse effects, and it was discussed this could be done by
the child’s General Practitioner (GP). However, PPI
members raised concern about getting access to GP ap-
pointments and research team members noted that it
would be difficult to make this a standard part of the
study protocol without involving GPs directly in the re-
search. Critically, after group reflection, it was agreed by
all members that having the first follow-up QbTest con-
ducted at 6–8 weeks would not allow for early identifica-
tion of sub-optimal responses, and could lead to a
lengthy titration schedule.
Recommendations
 If children have received a QbTest as part of
diagnostic assessment within 12 weeks before
medication initiation, no additional baseline QbTest
will be conducted. This diagnostic QbTest will be
used as the baseline assessment against which to
monitor medication effects.
 The first follow-up QbTest would be conducted 2–4
week after baseline. This time frame was selected
through group discussion to allow early monitoring
of adverse effects and sub-optimal response, but
provide a sufficient time window for organising
clinic appointments.
Q2: After the first follow-up assessment how fre-
quently should QbTest be repeated?
The need for QbTest to provide insight into the efficacy
of medication was counterbalanced by the additional de-
mand this places on clinicians and families. There was
consensus from all members that performing a QbTest as-
sessment at each dose titration would not be feasible.
Group one felt that two follow-up QbTests could be con-
ducted within the 12-week period (one at 1–2 weeks after
medication initiation and one at approximately 8–10
weeks), whereas during their initial discussions group two
had felt that only one follow-up QbTest was required (at
6–8 weeks with a telephone review at 2 weeks). The com-
bined group agreed that the clinician should not alter their
medication review process apart from adding the QbTest,
and thus supplementary telephone/clinic reviews could be
conducted in accordance to the clinician’s standard prac-
tice. It was also noted that the control group may not be
seen at all during the follow-up period and there was a
need to balance any effect of additional clinic contact. The
clinicians felt that arranging additional appointments to
treatment as usual in the control group would be a clinical
burden and not feasible, however, telephone contacts were
viable. The final recommendations to resolve the conflict-
ing opinions from group one and two were made through
whole group discussion, and the decision was partly based
on pragmatism and compromise between ‘best practice’
and ‘real world demands’. After this whole group discus-
sion, both groups endorsed the recommendations.
Recommendations
 After whole group reflection, it was agreed that a
second follow-up QbTest on medication should be
conducted within an 8–10 week period (and no
more than 12 weeks), to provide an additional op-
portunity to check medication response. This would
therefore lead to a protocol with one baseline as-
sessment, one follow-up assessment 2–4 weeks
after baseline/prescription of medication and a
final follow-up 8–10 weeks after baseline/prescrip-
tion of medication.
 There should be at least two contacts for
participants in the control group (which could be
conducted over the telephone during the follow-up
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period) to control for the additional assessments be-
ing conducted in the QbTest group.
Q3: How should we define the optimum dose?
Both group one and two expressed strong opinions
that the optimum dose should not be defined by reach-
ing a set score on a symptom rating scale. This was
unanimous across PPI members and clinicians who felt
that reaching a pre-defined score did not capture the
complex nature of ADHD, nor the impact of the symp-
toms on school, family and the young person. Import-
antly, PPI members noted the desire to have a child who
was a ‘true reflection of themselves’ and not over-
medicated to the point they lost ‘their personality’ and
‘the things that make them who they are’; rather, an
optimum dose would be one that reduced a child’s
symptoms until the condition was ‘manageable’.
Recommendations
 The definition of ‘optimal dose’ from which no
further adjustments are needed would be defined by
the clinician integrating the opinions of the young
person, the family and schools, alongside the QbTest
report in the QbTest group.
Workshop 2: study outcomes and instruments
The aim of the second workshop was to gain expert
opinion on which outcome measures should be used in
the research protocol and to ascertain the resource im-
plications of introducing QbTest for the NHS and a
broader societal perspective including the education sec-
tor and parents \ carers. It should be noted that for a
feasibility RCT the focus is on the completion rates of
outcome measures and the acceptability to the partici-
pants, rather than to collect sufficient data to conduct a
fully-powered definitive answer on effectiveness.
Seventeen experts, including six clinicians, four PPI
members, two researchers, two representatives from
MindTech, two advisors from Qbtech, and one health
economist, were divided into two groups. Group 1 (n =
8) primarily discussed possible outcome measures to as-
sess change in symptom or global functioning. Group 2
(n = 9) primarily discussed issues surrounding imple-
menting a health economic measure. Each group fo-
cussed on their assigned topic before feeding back to the
group as a whole.
Selecting suitable measures of symptom outcome and
global functioning
Group 1 were presented with a range of outcome mea-
sures typically used in ADHD research trials to guide
their discussion. They were informed that the SNAP-IV
(Swanson, Nolan, and Pelham Rating Scale [26]), a well-
used measure of ADHD symptoms, had previously been
selected by academic research team members as a highly
valuable assessment to include in this study as part of the
funding application. Therefore, the choice of this measure
was not part of the discussion. The group were asked to
discuss the possible use of six additional measures.
Strengths and Difficulties Questionnaire (SDQ) [27].
The SDQ provides a brief measure of behavioural and
emotional difficulties and was considered important to
use at baseline to help describe the core functioning and
behaviours of the sample. However, clinical and PPI
members unanimously agreed that the SNAP-IV com-
prehensively measured symptom change that was more
relevant to ADHD.
Children’s Global Assessment (CGAS) [28]. The CGAS
is a clinician completed measure of global functioning.
The CGAS was seen by clinicians as being too generic,
thus making it difficult to accurately complete. Both cli-
nicians and PPI members felt the data would not be
clinically meaningful due to this.
Clinical Global Impressions (CGI) [29]. The CGI is a
clinician-completed assessment of symptom severity and
improvement. Assessing these issues was seen as import-
ant by all members and the CGI was considered a quick
and easy method to achieving this. Both clinical and PPI
members felt that the clinician should complete this
measure as part of their consultation with the family,
reflecting joint rather than clinician-only judgements.
However, all parties observed that the wording of the
CGI was not always appropriate for children with
ADHD and that clinicians should be careful to re-phrase
the questions when discussing the CGI with the family.
A clinician with research expertise also pointed out that
completing the CGI throughout the intervention may in-
fluence clinicians’ practice, as such, it should only be
completed at baseline and at the end of the intervention.
EQ-5D-Y [30]. The EQ-5D-Y is a widely used assess-
ment of quality of life, comprised of a Likert scale and a
Visual Analogue Scale (VAS). The health economist and
research team members stressed the importance of hav-
ing a measure of quality of life. All group members con-
sidered the VAS as a user-friendly way to capture how
the young person felt in general. However, not all items
(e.g. mobility) were believed to be relevant to ADHD,
this was voiced by both clinicians and PPI members.
Child Health Utility 9D [31]. The CHU9D is a paediat-
ric quality of life measure for use in health care
resource-allocation decision making. This was discussed
as an alternative to the EQ-5D-Y. The group unani-
mously felt the questions such as being ‘worried’ or ‘sad’
were more relevant and the questionnaire was deemed
fit for inclusion.
Adverse Effects Scale [32]. This scale proved popular with
all group members, covering the key issues surrounding the
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impact of medication. A clinical academic lead highlighted
the importance of only the researchers having access to
parent and young person completed versions of this scale
so as not to influence practice. Alongside this, researchers
noted the importance of having a brief measure of medi-
cation adherence, to ensure participants were taking their
medication. Members felt this should be a simple question
which asks over the past 4 weeks how often has the child
taken their medication (every day, most days, occasionally,
never/withdrawn).
QbTest. All group members stressed the importance of
discussing the results of the QbTest with the family.
Their previous experience revealed this was not always
standard practice [19], and the need to interpret and dis-
cuss QbTest scores would be a key part of the study
protocol. It was also discussed whether the control
group should complete a QbTest at the second follow-
up (at 8–10 weeks), with the result being withheld from
the clinician until the participant exits the trial, so that
the scores can be used as an outcome measure. How-
ever, PPI members felt it was not ethical to bring fam-
ilies in to sit the test without receiving the benefits of
the results. Ultimately the PPI members’ concerns
(around the burden of gathering extra data without it
benefitting the child’s treatment) took precedence over
the desire for additional data from the control group.
Recommendations
 SDQ should only be used to describe the sample
characteristics at baseline rather than a measure of
outcome.
 CGAS should not be included as a measure.
 CGI should be completed at baseline and at the end
of the intervention through joint parent and clinical
discussions.
 CHU9D rather than the EQ5DY should be used as
the proxy of quality of life measure.
 Side effects scale should be included with an
additional medical adherence question.
 QbTest would not be conducted in the control arm
to monitor medication effects.
Capturing health and education resource use
Group 2 was co-led by the research team’s Health
Economist (MJ). The group discussed issues related to
capturing use of health services and used the Client Ser-
vice Receipt Inventory (CSRI) [33] as a starting point for
discussion. As an inventory, the CSRI allows researchers
to flexibly select the items best suited to the needs of
the individual research project.
The first issue centred on how often a measure of re-
source use should be completed in the trial. PPI mem-
bers discussed difficulties in recall, but also the burden
of completing the measure too frequently. They felt that
some items would remain the same (such as the school
the child attended) and over-duplication of the same in-
formation would be tiresome. However, other informa-
tion such as attending numerous clinic appointments
and seeing various healthcare professionals was difficult
to remember and they may not know the professional
background of their clinician (e.g. whether they have
seen a nurse or a psychiatrist). A member of the re-
search team suggested that participants could keep a
diary of appointments. However, consensus was not
reached on whether such an approach would capture
the important information or be feasible to implement
in this trial. The trial was not considered large enough
to test both options (standard health resource measure
completion vs. the diary method), but that this could be
an avenue for future research.
The second issue considered who should complete the
resource use questionnaire. The research team presented
the group with a modified CSRI, with instructions that the
items should only be viewed as starting point. Group
members believed that ideally parents should complete
this assessment, but the current format was complex and
didn’t lend itself to self-completion in its standard format.
In addition, its purpose was not immediately obvious from
the listed items, and the PPI members said it risked re-
sembling an assessment for state-funded financial aid
which could deter parents from completing it. They felt
that parents should receive a clear explanation from the
researcher before its completion. PPI members also noted
that they did not necessarily consider the economic im-
pact of ADHD as an important outcome, seeing improve-
ment in the symptoms as their main goal. Instead they
identified costs around the family/relationships (such as
parental stress and depression, parental sickness\absence
from work, relationship counselling and divorce) as im-
portant. Some of these are not captured in a typical stand-
ard CSRI form and although they were considered
important, it was outside the scope of this research to in-
clude these elements. Further research could investigate
the feasibility of collecting such outcomes. Although fi-
nancial costs, such as damage to household objects was
noted by PPI members (and recorded on the CSRI), it was
considered difficult to attribute a cost to these damages.
Using the full CSRI inventory was not considered to cap-
ture factors most important to families, and there was
concern the families would not complete the inventory as
a result. As such, consensus was reached that a purpos-
ively designed targeted resource use questionnaire should
preferably be administered as an investigator-based struc-
tured interview, with attention paid to explaining why this
assessment is carried out as part of the study.
The third issue discussed the questions which asked
about school resource use (such as receiving in-class
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support). PPI members and the education expert noted
that they may not always know the exact school re-
sources allocated to their child. Both these stakeholders
felt that schools were best placed to answer these ques-
tions, and the health resource use should be split into
two forms, one for school completion and one for the
family. The education expert noted the importance of
using the correct wording to describe school placements
and suggested that, where available, schools should also
provide the child’s Provision Map to accurately identify
resource use. On the basis of these discussions two draft
health resource use pro formas were created, the ‘Re-
source Use – Services in Education’ (RUSE) for school
completion and the ‘Resource Use – Services for Health
(RUSH)’ for families to complete (available on request
from the corresponding author).
Recommendations
 Repetition should be minimised; the CSRI inventory
should be used to inform a targeted resource use pro
forma (RUSH) only collecting data items that cannot
be retrieved from elsewhere in the study. To minimise
participant burden, items that are not expected to
change over time should not be included.)
 The targeted resource use questionnaire should be
administered as an investigator- based structured
interview, which can be done by telephone (with
clear explanation as to its purpose).
 The targeted health resource data collection tools
should be split into two forms, one for school
completion (RUSE) and one for the family (RUSH).
Workshop 3: selecting a primary outcome and recording
clinical decision making
The last workshop had the lowest attendance (n = 13,
62%). Reasons for non-attendance included annual leave
(4, 19%), prior clinical commitments (2, 9.5%), and feel-
ing that the protocol was sufficiently developed (2, 9.5%)
. The aim of the final workshop was to reflect on the
discussions, decide on a potential primary outcome and
develop a clinician completed pro-forma. Thirteen mem-
bers attended this workshop, including four clinicians, 4
PPI members, two researchers, two MindTech represen-
tatives and one advisor from Qbtech. The research team
presented the proposed study flow to the team (Fig. 1).
PPI members and clinicians felt that general function-
ing at school had not been adequately addressed, there-
fore a decision was made to include both a parent- and
teacher- completed SDQ at final follow-up to measure
change in global mental health difficulties. Although this
addition contrasts with the decision in workshop 1 not
to have a second SDQ at final follow-up, upon further
reflection the need to capture functioning at school was
considered important and felt to be best captured by the
SDQ, meriting inclusion as a secondary outcome meas-
ure. It was also noted that, where possible, the same
teacher should complete the baseline and follow-up
SDQs, but this was recognised to not always be possible
if follow-ups span changes in school years.
Developing a clinician completed pro forma
The expert members were presented with a clinician pro
forma used in a previous ADHD trial [20] which would
be necessary to record clinical decision making through-
out the trial. The members discussed issues around the
need to capture: the frequency and length of appoint-
ments, the timing of QbTest, a formal record that the
QbTest was discussed with the family, the methods used
to diagnose the young person, other methods used to in-
form monitoring and medication decision-making, the
drug and dose, and any other concomitant information.
Clinicians noted the importance of having simple-to-
complete questions using tick-boxes. A draft pro forma
was created on the basis of this which underwent two
rounds of further email discussions with the clinical
members before a finalised pro forma was reached. The
pro forma is included in Appendix 3. Additionally, clini-
cians felt that they were more likely to complete mea-
sures online than on paper as the latter would involve
an additional step of posting results back to the research
team. PPI members also felt online measure completion
was easier, however, families should be offered the op-
tion of postal or telephone completion for all outcome
measures to accommodate individual family preferences.
Selecting a primary outcome
The group were unanimous that a change on SNAP-IV
score should be the primary outcome. Symptom im-
provement was considered of key importance for both
clinicians and PPI members. The group discussed
whether reaching a normalised score was the best option
(as per workshop 1), however, as in the first workshop,
some clinicians felt that was not achievable, and PPI
members stressed the importance of having a child that
was a true reflection of themselves, and being ‘normal-
ised’ was not always desirable. Following the landmark
Multimodal Treatment of ADHD (MTA) [34], a 25% re-
duction of symptoms was considered the most suitable
primary outcome with normalization as secondary out-
come for a future definitive RCT.
After discussion, both parents and clinicians felt that
teachers were the best informants for completion of the
SNAP-IV. Although the team discussed issues around
potential low response rates from teachers, the clinicians
and PPI members felt teachers were still the best infor-
mants (due to medication often being given for optimum
effect during school hours and being able to compare
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with peers). The team concluded that teacher completion
rates will be monitored as part of the QUOTA feasibility
study to determine the suitability of teacher completed
SNAP-IV as the primary outcome for the future RCT. The
decisions made in the workshop, including the reasoning
behind them, were circulated to non-attending members
for their approval. All were in agreement.
Recommendations
 A parent and teacher completed SDQ should be
included at final follow-up to gain a measure of gen-
eral difficulties.
 A simple tick-box clinician completed pro forma
should be recorded online.
 Change (of 25%) on SNAP-IV score should be the
primary outcome.
 Teacher completion rates should be monitored as
part of the QUOTA feasibility study to determine
the suitability of teacher completed SNAP-IV in the
full RCT.
Discussion
The consensus workshops provided rich, multifaceted
information to support the development of an ADHD
medication management protocol for QbTest which
would be tested in a feasibility RCT. Given the increas-
ing awareness of the importance of involving patients,
caregivers and public members in research trials [35],
this methodologically-driven report has broad applicabil-
ity to researchers working in all fields of clinically-facing
research, but particularly for those working in ADHD
and other related areas such as in the child mental
health or neurodevelopment fields, who can draw upon
the preferences expressed to inform future trial design.
It was interesting to note the broad consensus across
both clinicians and PPI members in numerous areas,
with agreement on the need to balance the burden of
data collection against the need to gather important in-
formation. It is also noteworthy that many RCTs collect
multiple secondary outcomes which may not be pertin-
ent to the aim of the study. Our findings suggest these
should be streamlined in future research. Furthermore,
there was consensus across clinicians and PPI members
Participant identification and screening:
The clinical team invite eligible patients to the trial via letter of invitation and participant 
information sheets (age specific). Consent will then be obtained. 
Randomised:
Via sealed envelopes at clinic
Experimental arm (QbTest 
protocol)
Must have baseline QbTest at this 
appointment if not conducted
Appoint 1
(Baseline)
Control arm (Treatment as 
usual)
Follow standard treatment as 
usual
Research team collect: SNAP (P+T), SDQ (P + T), CHU9D
Clinician completes:  CGI and pro formas from this contact and everyone thereafter
Follow-up 1: 2-4 weeks later
1
st
QbTest on medication 
Follow up 
1
(2 – 4 wks)
Follow-up 1: 2-10 weeks later: 
clinician must hold at least  2
consultations with 2-10 week 
follow-up
Research team collect: SNAP (P+T), CHU9D, side effects + medication adherence
Follow-up 2: 8-10 weeks 
2nd QbTest on medication 
Follow up 2
(8 – 10 
wks)
max 12wk
Follow-up 2: 2-10 weeks later: 
clinician must hold at least 2 
consultations with 2-10 week 
follow-up
Research team collect: SNAP (P+T), SDQ (P+T), CHU9D, side effects + medication 
adherence, health resource use pro forma (P+T). Clinician completes:  CGI.
Clinicians and families invited for interview.
Fig. 1 Study Flow
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that the importance of reaching a meaningful reduction
in symptoms was more important than achieving a ‘nor-
malised’ score. When selecting primary outcomes there
can be a tendency for research teams to define clinically
meaningful change from a clinician’s perspective, how-
ever, the opinion and lived experience of the patient and
caregiver should inform this judgement.
Members of the consensus workshop were over-
whelmingly positive about their experience of being part
of the group, with each member feeling they had an op-
portunity to be heard. A protocol was developed on the
basis of these workshops, which has been published [13].
The QUOTA study is in the early stages of participant
recruitment so we cannot comment on whether recruit-
ment was successful or protocol adherence was good as
a result of this approach to its development. The
QUOTA study will record and publish these outcomes
as part of the feasibility assessment. It is recognised that
it is difficult to record, measure and quantify the impact
that involving patient and public members in research
may have. To discern the impact that PPI members had
in this instance, we have recorded where they contrib-
uted (and where they did not) which provides a route
into charting their impact on decision making; logging
of recommendations is a helpful way to capture impact
[36]. It is not possible to know exactly how the protocol
would have differed without PPI inclusion (as with the
removal of any expert from the process) but mapping
their specific contribution to decision making can help
to reveal a footprint of sorts.
We now consider specific of the workshop design and
identify possible areas for further research. One of the chal-
lenges of conducting the workshops was the need to balance
opinions for ‘best practice’ with real-world time and finance
constraints. There also remain challenges around whose
viewpoint holds prominence when there are competing
views. A key example is where the workshops highlighted
outcomes that mattered to parents (relating to changes in
the impact of the child’s ADHD on family life more gener-
ally) but would be difficult to capture and had less relevance
to clinical outcomes. Given the constraints of the study,
these were ultimately considered secondary to the other re-
search aims (by the researchers, at least). However, this
would be a useful development for future research in this
field. Additionally, some points were raised (such as modifi-
cations to the methodology of completing economic mea-
sures through the diary method) which were outside the
remit of this study to investigate. In terms of limitations, des-
pite good representation across key stakeholders, our find-
ings reflect the opinions of members who agreed to
participate in the groups, who may be specifically motivated
to develop a more closely-monitored titration process. Fur-
thermore, the participants were invited through the study
team’s known contacts in the field (including an ADHD
support group for parents) and participation was not adver-
tised. Additionally, it was not possible for children or young
people to participate in the workshops. Although our invita-
tion to participate was extended to both parents and their
child, difficulties in organising groups outside of school hours
and the nature of the workshops (several hours of focussed
time), precluded young people from attending. Designs that
provide a more child-friendly format would be useful in fu-
ture to ensure the views of this group are included.
In the current study, each workshop comprised a slightly
different format: two comprised small sub-groups (in one
the same point was discussed and in the other the groups
discussed separate points); the third involved whole-group
discussion only. This was a reactive decision, rather than
pre-planned, driven by the number of people available to
attend each workshop (there were fewer people available
for the third workshop) and time limitations. However, the
choice was also strategic. The first workshop covered the
most fundamental basic outline of the design on which
consensus had to be obtained to allow progression; this was
the most important element of its design and was given the
most attention by making it the focus of discussion for both
sub-groups. In the second workshop, although participants
discussed different topics, they presented their discussions
to the other group to ensure whole-group discussion. The
third workshop (with no sub-groups) was designed to en-
courage discussion by all participants. At this stage, the
members felt comfortable with all other members and thus
smaller groups would not have been as necessary. Although
maintaining the same format for every workshop would
have led to greater consistency in the methodology, the
more flexible approach chosen here ensured that the group
format was best suited to the topics for discussion at each
point and the group numbers at each stage. Further re-
search could investigate the extent to which the structure
and make-up of groups is best kept constant or should be
made flexible to elicit information effectively.
It could be argued that a group approach can be less
likely to elicit contradictory views or views that deviate
from the norms being expressed, resulting in the most
prevalent or forcefully expressed viewpoints dominating
group discussion. To mitigate this, workshop facilitators
were briefed in advance and instructed to give focus to
PPI members as much as possible in order to seek their
viewpoints in particular. Indeed, PPI co-applicant (NB)
was involved in planning the workshops and was aware
a key task would be to create a process that allowed PPI
members to contribute freely. Furthermore, some of our
PPI members were also partially chosen for their confi-
dence and ability to express their opinion, and were able
to create a welcoming environment to support other PPI
members. Alternative methodological approaches in-
clude interviews with individual participants or a Delphi
survey. Given the need to develop a study protocol that
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reflected the needs and views of different stakeholders,
we felt the group method was preferable to individual
interviews [36]. The Delphi method requires individual
participants to answer questions/rate items and give
feedback (usually remotely) which is collated by the re-
search team. The protocol is then refined and partici-
pants are asked to re-rate each item. Although this
approach ensures that individuals are not unduly influ-
enced by a group-norm, it is timely and costly. More-
over, we felt that the information gathered through
group discussions would be richer and enable a more
meaningful consensus to be reached, driven by the
stakeholders, rather than the researchers. Furthermore,
built into the study design (but not part of the work-
shops) is a phase of qualitative data collection (work-
shops and interviews) exploring the experience of the
protocol from clinician and family perspectives – both
in a combined group setting and also individually in in-
terviews – to draw out what its impact was in practice,
and whether further adaptations to the protocol are re-
quired. So whilst the protocol design phase used group
discussion alone, this sits within a broader inquiry that
uses additional methods.
It should be noted that although this design was
specific to designing a medication protocol for chil-
dren, the concept of the formulation and delivery of
the workshop, with relevant PPI members is pertinent
for any trial involving human participants. We would
also like to emphasise that although involving differ-
ent stakeholders is an important and under-practiced
part of research design, this should not be the exclu-
sive process in designing a trial. Considerations for
quality standards and scientific rigour must always be
of paramount importance.
Conclusions
By presenting the approach and findings of the work-
shops involving multidisciplinary members to develop a
medication and trial protocol, we illuminate some of the
consultative processes under-pinning the development
of clinical protocols to enhance their acceptability and
feasibility. By sharing our methodological approach, we
hope to improve the transparency of protocol develop-
ment and strongly advocate that researchers actively
engage with clinical teams, industry, and patient and
public members when developing protocols. Protocols
which are co-developed may help overcome some of the
barriers associated with successful completion of RCTs,
such as issues with recruitment, retention and adher-
ence. Our methodology and findings may also be useful
for groups and organisations that develop clinical con-
sensus guidelines, and for clinicians and researchers
working in the field of ADHD in particular.
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